<DOC>
	<DOCNO>NCT01070667</DOCNO>
	<brief_summary>The purpose study accurately investigate efficacy dronedarone maintain sinus rhythm decrease AFB patient paroxysmal atrial fibrillation compare placebo . This never previously perform use pacemaker Holter monitoring provide detailed information atrial arrhythmia pattern entire study period . Additionally detailed patient symptom self assessment questionnaire collect . The study design double blind crossover phase last 3 month .</brief_summary>
	<brief_title>Dronedarone Pacemakers Patients With Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>The study plan commence March 2010 obtain Ethics Committee approval . Patients randomise three month course dronedarone placebo . 1:1 double blind randomisation undertaken . At three month , one week washout period , patient cross-over treatment group . To achieve power 0.8 type one error rate 5 % detect relative difference 10 % primary outcome study require 42 patient . 50 patient total enrol study . The study take place Eastbourne District General Hospital . The study duration per patient 7 month . The overall study duration 1 year . STUDY OVERVIEW Appropriate patient DDDRP pacemaker AF burden 1-50 % detect pacemaker holters identify pace clinic list Cardiology Outpatient Department Eastbourne District General Hospital . They invite take part verbal explanation study give . If agreement obtain patient give Patient Information Sheet allow time consider participation study ask relevant question . If still agreement ask sign Patient Consent Form . Initially , patient baseline parameter assess . All patient stop take anti-arrhythmic drug period one week . Patients three month course either dronedarone placebo accord randomisation double blinded fashion . Randomisation perform use random number table . At three month data collect patient questionnaire pacemaker Holter . There one week washout period time . Patients cross-over dronedarone placebo three month period . Data patient questionnaire pacemaker Holters collect three month cross-over . Patients undergo week washout period re-initiating original anti-arrhythmic therapy .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients paroxysmal atrial fibrillation ( AF burden 150 % define DDDRP PPM ) 3 month prior induction study . Patients DDDRP pacemaker implant primary secondary indication . Patients must warfarin . Patients must 18 year old . Patients give informed consent form prior participate study . Current previous treatment amiodarone . Patient suffer unstable angina last 1 week . Patient myocardial infarction within last 2 month . Patient expect major cardiac surgery within last 2 month . Patient participate conflict study . Patient mentally incapacitate consent comply followup . Patient NYHA class III/ IV heart failure . Pregnancy . Patient suffers cardiac rhythm disorder . Recent coronary artery intervention factor suggest clinical instability ( ECG , clinical laboratory finding ) . GFR &lt; 30mls/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PAF</keyword>
	<keyword>AF</keyword>
	<keyword>Dronedarone</keyword>
	<keyword>AF Burden</keyword>
	<keyword>AFB</keyword>
	<keyword>PPM</keyword>
	<keyword>Permanent Pacemaker</keyword>
	<keyword>Atrial Fibrillation Burden Paroxysmal Atrial Fibrillation</keyword>
</DOC>